NAVIGATION
 
> Home
> OPPI Vision
> Office Bearers 
> Committees
> News and Events
> OPPI in Media - 2010 to date - News at a glance
> OPPI Position on IPR
> Pharma Spectrum - Monthly News At A Glance
> OPPI Position Paper on Biosimilars
> OPPI Position on Data Protection
> OPPI Anti - Counterfeiting Guidelines
> A Handy Guide for Road Safety
> OPPI IPR Symposium Videos
> Patents
> Drug Policy & Pricing
> Regulatory
> Links
> India OTC Pharmaceutical Profile 2011
   
 

 

IFPMA Clinical
Trials Portal

IFPMA - Improving
Global Health


OPPI Guidelines on
Cold Chain
Pharmaceutical Products


OPPI - YES Bank Report,
Pharmaceutical Industry:
Vision 2015


OPPI IPR
Symposium Proceedings

 




About Us Members Publications Contact Us Member Login
 
  OPPI NEWS
 

Patent Bill to Hurt Public Interest: Expert
September 21, 2009, Mint

A patent and intellectual property rights Bill modelled on a 1980 Act of the US Congress and due to be tabled in
the Parliament’s December session is drawing criticism from researchers and academics for not addressing key
issues and jeopardizing public interest. Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, an industry body that represents foreign drug firms operating in India, said, “The core concept of the Bill encourages innovation and ensures protection of patents and other forms of IP rights of the government-funded R&D outcomes, where the owner of the intellectual property will be the government grant recipient or the government.



            Copyright © 2011. Organisation of Pharmaceutical Producers of India. All Rights Reserved.  |   Disclaimer  |